FUJIFILM Cellular Dynamics: Human Cells. Endless Possibilities from Discovery to Regenerative Medicine. FCDI Notebook
TrendingArticlesDigital Media
FCDI Notebook
Welcome to FCDI Notebook
Trending

FCDI Expands Their Range of Cardiac Disease Models.

Study disease relevant mutations with isogenic cardiomyocyte pairs: Elucidate the functional consequences of potentially life-threatening hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and Brugada Syndrome (BrS) mutations. See the latest models:

Articles
Role of Mcl-1 in regulation of cell death in human induced pluripotent stem cell-derived cardiomyocytes in vitro.

Role of Mcl-1 in Regulation of Cell Death in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes in Vitro

Discover how researchers at the NIH used the iCell Cardiomyocytes to elucidate on-target cardiotoxicity due to chronic Mcl-1 knockdown on human cardiomyocytes

Guo L., Eldridge S., Furniss M., Mussio J., and Davis M.
Toxicol Appl Pharmacol. 2018 Dec 1; 360:88-98.

ARTICLE >>


Application of human induced pluripotent stem cell-derived cardiomyocytes sheets with microelectrode array system to estimate antiarrhythmic properties of multi-ion channel blockers.

Application of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Sheets with Microelectrode Array System to Estimate Antiarrhythmic Properties of Multi-ion Channel Blockers.

See how researchers at Toho University and National Institute of Health Sciences used sheets of iCell Cardiomyocytes to quantify the electropharmacological profile of known drugs.

Izumi-Nakaseko H., Hagiwara-Nagasawa M., Naito AT., Goto A., Chiba K., Sekino Y., Kanda Y., and Sugiyama A..
J Pharmacol Sci. 2018 Aug;137(4):372-378.

ARTICLE >>

FCDI in the News
New FCDI cGMP Facility for iPSC Manufacturing

FUJIFILM Cellular Dynamics to Establish New Facility for Production of Human iPS Cell Therapy Applications

FUJIFILM Cellular Dynamics, Inc. has announced an investment of about $21 million to open a new cGMP-compliant*1 production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies.

SEE THE PRESS RELEASE>>

Applications
Implementing Human iPSC-derived Cells in Early Safety Assessment and Disease Modeling

FCDI Presentation at Safety Pharmacology Society 2018:

Implementing Human iPSC-derived Cells in Early Safety Assessment and Disease Modeling

In case you missed it, see the Fujifilm Cellular Dynamics, Inc. and Nanion Technologies, GmbH, presentation from SPS 2018

Discussion topics include evaluation of the sodium-calcium exchanger (NCX) using the SURFE2R 96SE and CardioExcyte 96 and the effect of CiPA drugs on iCell Cardiomyocytes

SEE THE VIDEO >>

Follow UsFCDI TwitterFCDI LinkedInFCDI FacebookFCDI Youtube

© 2019 FUJIFILM Cellular Dynamics, Inc., 525 Science Drive, Madison, WI 53711
+1 (608) 310-5100 or toll-free (877) 310-6688
fujifilmcdi.com